PlantForm is a pioneer in plant-based biologics, and at the forefront of developing Biosimilar drugs for cancer and other indications. Their pipeline is also heavily focused on Biodefense medical countermeasures to key terrorism threats such as ricin and sarin gas. They are currently working with several Departments of Defense, including Canada, U.K., Australia, and the U.S. Defense Advanced Research Projects Agency (DARPA). PlantForm’s patented vivoXPRESS® plant-based technology platform is designed to deliver a wide range of Biopharmaceutical products, including therapeutic and medical countermeasure drugs. Their Biosimilars will include versions of market-leading drugs like Keytruda and Lucentis, as well as novel treatments to counteract nerve agents. The are currently manufacturing their HIV product in Holland & Belgium, with several commercially viable solutions in their pipeline set to hit market over the next few years. https://uscapglobalsecurities.docsend.com/view/jx2bxdazvrebgnrm/d/qpdbcmjfy4ehw3gy